research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
Search
for
Sort by
Research
30 / 1000+ results 
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research A Concise Review on Novel Drugs Applied in Treatment of Alopecia
New therapies like JAK inhibitors, PRP, and stem cell treatments show promise for better alopecia management.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
New medications could improve treatment for severe alopecia areata in Australia.
research Aim to alleviate alopecia areata with newly available agents
New treatments like JAK inhibitors offer hope for better alopecia areata management.
research Exploring novel management options for alopecia areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Off-Label Treatment of Alopecia Areata—Retrospective Study
Off-label treatments are heavily used for alopecia areata due to limited approved options.
research Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.
research Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Dupilumab helps children with alopecia areata regrow hair safely.
research Methods of Using of Cosmeceuticals in Trichological Practice
Use personalized cosmeceuticals for safe, effective hair and scalp treatment.
research Patient Validation of Estimation of Health Utility Values in Alopecia Areata
Patients with Alopecia Areata are willing to trade life duration for better quality of life.
research Novel drugs of United States Food and Drug Administration approved in 2024
In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.
research The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto ( Serenoa repens ) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self‐Perceived Thinning Hair: 90‐Day Results
Saw palmetto extract safely improves hair growth and reduces hair loss.
research 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
Baricitinib stops hair loss and promotes regrowth in alopecia areata.
research Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.